Brain derived neurotrophic factor (BDNF) Val66Met polymorphism is not risk factor for bipolar disorder

Vandana Rai*, Farhin Jamal, Pradeep Kumar

Department of Biotechnovogy

V B S Purvanchal University

Jaunpur-222003,UP

Correspondence: *raivandana@rediffmail.com

Abstract:

Bipolar disorder (BPD) is a psychiatric disease, characterized by the cycles of mania and depression. Several genetic studies investigated BDNF gene Val66Met polymorphism as risk factor for BPD, but results were inconclusive. Therefore, present meta-analysis was performed to reevaluate the BDNF Val66Met polymorphism and BPD association. Four databases (Pubmed, Springer Link, Science Direct and Google Scholar) were searched for eligible studies up to March 31,2018. Pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated to estimate the strength of the association. All statistical analyses were done by MetaAnalyst and Mix program. Forty studies with a total of 28,787 subjects (10,085 cases and 18,702 controls) were included in this meta-analysis. Overall, pooled analysis indicated that there was no significant association between BDNF Val66Met polymorphism and BPD risk under all five genetic models ($OR_{A \text{ vs. } G} = 0.99$, 95%CI= 0.94-1.03, $p=0.49$; $OR_{AG \text{ vs. } GG} = 0.102$, 95%CI= 0.95-1.07, $p= 0.57$; $OR_{AA \text{ vs. } GG} = 0.98$, 95%CI=0.89-1.08, $p=0.75$; $OR_{AA+AG \text{ vs. } GG} = 1.0$, 95%CI= 0.94-1.06, $p= 0.89$; $OR_{AA \text{ vs. } AG+GG} = 0.96$, 95%CI= 0.89-1.05, $p= 0.47$). Similarly, no significant association was observed in ethnicity based subgroup analysis in both Asian and Caucasian population. However, significant association was found in subtype analysis between BDNF Val66Met and BPDII ($OR_{AA+AG \text{ vs. } GG} = 1.21$, 95%CI= 1.06-1.37, $p= 0.003$) but not with BPD I. These findings suggested that the BDNF Val66Met polymorphism confer no genetic susceptibility to BPD I but risk for BPDII.

Keywords: Bipolar disorder, BPD, BDNF, Val66Met, Polymorphism, meta-analysis

Introduction:

Bipolar disorder (BPD) is one of the most common and severe psychiatric disorder, which is classified as a mood disorder in the Diagnostic and statistical Manual of Mental Disorders(DSM IV) (American Psychiatric Association,2000). World Health Organization has identified BPD as the sixth leading cause of disability in the world(WHO,2004). The lifetime prevalence of BPD is estimated to be between 1% and 2% (Kessler et al.,1994; Merikangas et al.,2007). The disorder is characterized by episodes of mania, with elated or irritable-angry mood and symptoms like pressured speech, racing thoughts, grandiose ideas, increased energy, and reckless behavior, alternating with more normal periods and, in most cases, with episodes of depression. Although the etiologic mechanisms for BPD are not well known, it has been hypothesized that both environmental and genetic factors play important roles, and multiple genes contribute to risk of the disease (Hawton et al.,2005; Goodwin,20012).

BDNF is one of the most studied and abundant neurotrophin in central nervous system, which plays an important role in a variety of neural processes. During, BDNF is essential for neurogenesis, neuronal survival, and neural development pathways. In the adult, BDNF is important for synaptic plasticity, dendritic growth and long-term memory consolidation (Post,2007). Because of the diverse functions of BDNF protein, BDNF gene is a good candidate for the susceptibility to different neuropsychiatric disorders including BPD (Goldberg et al.,2008).

Several polymorphisms are reported in BDNF gene, but in exon 5 G to A (G196A) transition (dbSNP: rs6265) at position 196 is most studied and clinically important. G196A polymorphism produces amino acid substitution of valine (Val) to methionine (Met) at codon 66(Val66Met) in the 5' prodomain in the BDNF protein (Cargill et al.,1999). This substitution from valine (Val) to methionine (Met) at codon 66 has functional consequences (Egan et al.,2003; Chen et al.,2006). The Met (A) allele of the precursor peptide has been associated with impaired intracellular trafficking of pro-BDNF into dendrites and vesicles as well as a reduction inactivity-dependent secretion, the process that plays a major role in the regulation of extracellular levels of BDNF (Egan et al.,2003; Chen et al.,2006). The frequencies of the Val and Met alleles of BDNF Val66Met vary by ethnicity; about 80% of the European population has Val allele while only 50% of Asian has it (Pivac et al.,2009). Numerous studies investigated Val66Met polymorphism as a risk factor for BPD but results were inconclusive. Hence, authors performed present meta-analysis to reevaluate the association between BDNF Val66Met polymorphism and BPD risk.

Methods:

Meta-analysis was carried out according to Meta-analysis of observational studies in epidemiology (MOOSE) guidelines (Stroup et al.,2000).

Search Strategy:

A literature search was performed for available articles that were published up to March 31, 2018 from the following databases: (1) Pubmed; (2) Google Scholar; (3) Science Direct; and (4) Springer Link. The search used the following keywords: “Bipolar Disorder” or “BPD” and “brain-derived neurotrophic factor” or “BDNF” and “Val66Met”. We also reviewed the bibliography of included articles to identify additional articles not retrieved by database search.

Inclusion and exclusion criteria:

The following inclusion criteria were used: (i) studies should be original, (ii) used case control approach, and (iii) used standard diagnostic criteria for bipolar disorder patient diagnosis (Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) or the International Classification of Diseases (ICD). Studies were excluded if: (i) incomplete raw data information like- number of genotype/allele, and (ii) studies based on pedigree data.

Data Extraction:

Relevant information were extracted from all selected studies like- first author's name, year of publication, country name, ethnicity, sample size and number of cases and controls for BDNF Val66Met genotypes (GG, AG and AA). Mutant allele frequencies for the cases and controls were calculated from corresponding genotypes. Allele frequency was calculated by simple gene count method.

Statistical analysis:

The present meta-analysis examined the overall association of Met allele with the risk of bipolar disorder. Pooled odds ratio (OR) with 95% confidence interval (CI) was used as association measure, which was estimated either by fixed effect (Mantel and Haenszel, 1959) or random effect (DerSimonian and Laird, 1968) models depending upon heterogeneity. Heterogeneity was tested by Q-statistics and quantified by the I^2 statistic (Higgins and Thompson, 2002). If $I^2 > 50\%$ then random effect model was used (Whitehead, 2002). Genetic models were chosen according to the method of Thakkestian et al. (2005), briefly calculating and comparing the ORs of A(Met) vs. G (Val) (allele contrast), AA(Met/Met) vs. GG(Val/Val) (homozygote), AG(Met/Val) vs. GG(Val/Val) (co-dominant), AA(Met/Met) + AG(Met/Val) vs. GG (Val/Val) (dominant) and AA(Met/Met) vs. AG(Met/Val) + GG(Val/Val) (recessive) models. We have also done sub-group analysis based on ethnicity and subtypes of bipolar disorder like BPD I and BPD II. In allele contrast meta-analysis, sensitivity analysis performed by exclusion of the studies in which control population was not in Hardy Weinberg equilibrium and studies with small sample size.

Publication bias:

Publication bias was investigated by funnel plots; viz. funnel plot of standard error by log odds ratio and funnel plot of precision (1/standard error) by log odds ratio. Different statistical tests such as Begg and Mazumdar rank correlation (Begg and Mazumdar, 1994) and Egger's regression intercept (Egger et al., 1997) were adopted to assess the publication bias. All p values were two tailed with a significance level at 0.05. All statistical analyses were undertaken using program MetaAnalyst (Wallace et al., 2013) and MIX version 1.7 (Bax et al., 2006).

Results:

Characteristics of included studies:

The study search workflow was shown in Figure 1. The preliminary search resulted in 187 publications from Pubmed, Springer Link, Science Direct and Google Scholar. Out of which 104 articles were excluded after title and abstract reading. Again 23 articles including review, letter to editors and comment were excluded from remaining 83 articles. Further 26 articles, which were duplicate studies, studies without genotype or allele number, studies on animal models, were excluded. Out of 34 remaining articles, 3 articles were meta-analysis, and excluded. Thus, total thirty studies that investigated the association of BDNF Val66Met polymorphism with BPD were found suitable for the inclusion in the present meta-analysis (Hong et al., 2003; Nakata et al., 2003; Kunugi et al., 2004; Oswald et al., 2004; Skibinska et al., 2004; Lohoff et al., 2004; Nerves-Pereira et al., 2005, 2011; Schumacher et al., 2005; Green et al., 2006; Liu et al., 2007; Tramontina et al., 2007; Kim et al., 2008; Vincze et al., 2008; Tang et al., 2008; Xu et al., 2009; Hosang et al., 2010; Carrard et al., 2011; Huang et al., 2012; Pae et al., 2012; Wang et al., 2012; Lee et al., 2012; Min et al., 2012; Chang et al., 2013; Lee et al., 2013; Gonzalez-Castro et al., 2014; Frazier et al., 2014; Kenna et al., 2014; Nassan et al., 2015; Morales-Marín et al., 2016). In nine articles, authors (Nakata et al., 2003; Kunugi et al., 2004; Green et al., 2006; Xu et al., 2009; Huang et al., 2012; Wang et al., 2012; Lee et al., 2012; Chang et al., 2013; Kenna et al., 2014) investigated subtypes of bipolar disorder like BPD I and BPD II. We included each case sample group (BPD I and BPD II case samples) as separate article so total forty article were included in the present meta-analysis (Table 1).

In forty included studies, the smallest case sample size was 26 (Kenne et al., 2014) and highest sample size was 864 (Green et al., 2006). In included studies, total cases and controls were 10,085 and 18,702 respectively. In controls genotype percentage of GG, AG and AA were 47.73%, 40.09% and 12.18% respectively. In cases genotype percentage of GG, AG and AA were 52.63%, 36.59% and 10.23% respectively. Control population of three studies (Nerves-Pereira et al., 2011; Wang et al., 2012; Lee et al., 2013) was not in Hardy-Weinberg equilibrium (Table 1). Case and control subjects were selected from following countries- Brazil (Tramontina et al., 2007; Nerves et al., 2011), Bulgaria (Oswald et al., 2004), China (Hong et al., 2003; Liu et al., 2007; Tang et al., 2008; Xu et al., 2009;

Wang et al., 2012; Lee et al., 2012; Chang et al., 2013; Lee et al., 2013), France (Vincze et al., 2008), Germany (Schumacher et al., 2005), Japan (Nakata et al., 2003; Kunugi et al., 2004), Korea (Kim et al., 2008; Pae et al., 2012; Min et al., 2012), Mexico (Gonzalez-Castro et al., 2014; Morales-Marín et al., 2016), Scotland (Nerves-Pereira et al., 2005), Taiwan (Huang et al., 2012), UK (Green et al., 2006; Hosang et al., 2010), USA (Lohoff et al., 2004; Frazier et al., 2014; Kenna et al., 2014; Nassan et al., 2015), Wielkopolska (Skibinska et al., 2004).

Meta-analysis:

Meta-analysis with allele contrast (A (Met) vs. G(Val)) showed no association with both fixed effect ($OR_{A \text{ vs. } G} = 0.99$, 95%CI= 0.94-1.03, $p=0.49$) and random effect model ($OR_{A \text{ vs. } G} = 0.98$, 95%CI= 0.93-1.03, $p=0.46$) (Table 2; Figure 2). Significant association was not found between BPD and mutant genotype (AA vs. GG; homozygote model) with both fixed ($OR_{AA \text{ vs. } GG} = 0.98$, 95%CI=0.89-1.08, $p=0.75$) and random ($OR_{AA \text{ vs. } GG} = 0.98$, 95%CI=0.87-1.10, $p=0.74$) effect models (Table 2; Figure 2). Mutant heterozygous genotype (AG vs. GG; co-dominant model) meta-analysis did not show any significant association with BPD using fixed ($OR_{AG \text{ vs. } GG} = 0.102$, 95%CI= 0.95-1.07, $p=0.57$) and random ($OR_{AG \text{ vs. } GG} = 1.02$, 95%CI= 0.93-1.13, $p=0.56$) effect models (Table 2). Combined mutant genotypes (AA+AG vs. GG; dominant model) meta-analysis showed negative association with BPD using both fixed ($OR_{AA+AG \text{ vs. } GG} = 1.0$, 95%CI= 0.94-1.06, $p=0.89$) and random ($OR_{AA+AG \text{ vs. } GG} = 1.0$, 95%CI= 0.92-1.09, $p=0.86$) effect models. Similarly the recessive genotypes model (AA vs. AG+GG) also did not show any association fixed ($OR_{AA \text{ vs. } AG+GG} = 0.96$, 95%CI= 0.89-1.05, $p=0.47$) and random ($OR_{AA \text{ vs. } AG+GG} = 0.96$, 95%CI= 0.86-1.06, $p=0.45$) effect models (Table 2).

Subgroup analysis:

Out of 40 studies included in the present meta-analysis, 21 studies were carried out on Asian subjects, and 19 studies were carried out on Caucasian population. The subgroup analysis by ethnicity revealed that no significant association existed between BDNF Val66Met polymorphism and BPD in Asian population ($OR_{A \text{ vs. } G} = 1.02$, 95%CI= 0.96-1.07, $p=0.47$; co-dominant model- $OR_{AG \text{ vs. } GG} = 1.08$, 95%CI= 0.99-1.18, $p=0.07$; homozygote model- $OR_{AA \text{ vs. } GG} = 1.05$, 95%CI=0.94-1.17, $p=0.34$; dominant model- $OR_{AA+AG \text{ vs. } GG} = 1.07$, 95%CI= 0.98-1.16, $p=0.09$; recessive model- $OR_{AA \text{ vs. } AG+GG} = 1.01$, 95%CI= 0.92-1.11, $p=0.79$) (Table 3, Figure 3). Similarly in Caucasian subgroup analysis, heterogeneity was low and except allele contrast model, significant association was not found between C677T polymorphism and BC risk ($OR_{A \text{ vs. } G} = 0.93$, 95%CI= 0.87-0.99, $p=0.003$; co-dominant model- $OR_{AG \text{ vs. } GG} = 0.96$, 95%CI= 0.89-1.04, $p=0.34$; homozygote model- $OR_{AA \text{ vs. } GG} = 0.80$, 95%CI=0.65-0.98, $p=0.03$; dominant model- $OR_{AA+AG \text{ vs. } GG} = 0.94$, 95%CI= 0.87-1.02, $p=0.14$; recessive model- $OR_{AA \text{ vs. } AG+GG} = 0.79$, 95%CI= 0.65-0.95, $p=0.02$) (Table 3, Figure 4).

Subgroup analysis based on subtypes of BPD like BPD I and BPD II was also performed. Out of 40 studies, in 12 studies cases were of BPD I and in 10 studies, authors selected BPD II cases for their analysis. In other studies, type of bipolar disorder was not mentioned, so we grouped them in one subgroup (BPD subgroup). Meta-analysis of BPD I studies did not show any association between Val66Met and BPD I ($OR_{A \text{ vs. } G} = 0.98$, 95%CI= 0.93-1.06, $p=0.95$; co-dominant model- $OR_{AG \text{ vs. } GG} = 0.93$, 95%CI= 0.85-1.02, $p=0.16$; homozygote model- $OR_{AA \text{ vs. } GG} = 1.06$, 95%CI=0.91-1.23, $p=0.43$; dominant model- $OR_{AA+AG \text{ vs. } GG} = 0.95$, 95%CI= 0.83-1.04, $p=0.26$; recessive model- $OR_{AA \text{ vs. } AG+GG} = 1.08$, 95%CI= 0.94-1.20, $p=0.23$) (Table 3). Meta-analysis of BPD II studies showed significant association between BDNF Val66Met polymorphism and BPD II except recessive model ($OR_{A \text{ vs. } G} = 1.10$, 95%CI= 1.01-1.21, $p=0.04$; co-dominant model- $OR_{AG \text{ vs. } GG} = 1.31$, 95%CI= 1.06-1.60, $p=0.03$; homozygote model- $OR_{AA \text{ vs. } GG} = 1.11$, 95%CI= 1.01-1.23, $p=0.03$; dominant model- $OR_{AA+AG \text{ vs. } GG} = 1.21$, 95%CI= 1.06-1.37, $p=0.003$; recessive model- $OR_{AA \text{ vs. } AG+GG} = 0.96$, 95%CI= 0.83-1.12, $p=0.06$) (Table 3).

Again subgroup BPD meta-analysis did not show any association between Val66Met polymorphism and BPD ($OR_{A \text{ vs. } G} = 0.95$, 95%CI= 0.89-1.02, $p=0.24$; co-dominant model- $OR_{AG \text{ vs. } GG} = 1.02$, 95%CI= 0.93-1.12, $p=0.63$; homozygote model- $OR_{AA \text{ vs. } GG} = 0.82$, 95%CI=0.68-0.98, $p=0.03$; dominant model- $OR_{AA+AG \text{ vs. } GG} = 0.99$, 95%CI= 0.90-1.08, $p=0.88$; recessive model- $OR_{AA \text{ vs. } AG+GG} = 0.82$, 95%CI= 0.70-0.96, $p=0.02$) (Table 3).

Heterogeneity and Sensitivity analysis:

Between studies heterogeneity existed moderate heterogeneity in allele contrast ($P_{\text{heterogeneity}} = 0.02$, $I^2 = 34.64$), high heterogeneity in co-dominant ($P_{\text{heterogeneity}} < 0.0001$, $I^2 = 54.68$), insignificant low heterogeneity in homozygote ($P_{\text{heterogeneity}} = 0.13$, $I^2 = 20.43$), moderate heterogeneity in dominant ($P_{\text{heterogeneity}} = 0.0007$, $I^2 = 46.83$) and low heterogeneity in recessive ($P_{\text{heterogeneity}} = 0.09$, $I^2 = 23.92$) comparisons (Table 2).

Sensitivity analysis was performed by eliminating studies with small sample size (<100) and control population deviating from HWE. Control population of three studies was not in HWE (Nerves-Pereira et al., 2011; Wang et al., 2012; Lee et al., 2013) and heterogeneity was not decreased after exclusion of these studies ($I^2 = 34.4\%$; $p=0.02$). Sample size of six studies was less than 100 (Nakata et al., 2003; Green et al., 2006; Xu et al., 2009; Wang et al., 2012; Kenna et al., 2014; Marin et al., 2016) and after exclusion of these studies heterogeneity was decreased ($I^2 = 34.5\%$; $p=0.027$).

Publication bias:

Funnel plots and Egger's test were performed to estimate the risk of publication bias. Except recessive model, publication bias was absent (A vs. G: $P_{\text{Egger's test}} = 0.09$; AG vs. GG: $P_{\text{Egger's test}} = 0.49$; AA vs. GG: $P_{\text{Egger's test}} = 0.05$; Dominant model AA+AG vs. GG: $P_{\text{Egger's test}} = 0.81$; Recessive model AA vs. AG+GG: $P_{\text{Egger's test}} = 0.02$).

Discussion:

Forty case-control studies with 10,085 bipolar disorder cases and 18,702 controls were included in the present meta-analysis. The results of current meta-analysis indicated that the Met (A) allele of BDNF was not associated with risk of BPD. Further, subgroup analyses based on ethnicity also did not show any association between BDNF Val66Met polymorphism and BPD in Asian as well as Caucasian populations. However, subgroup analysis based on BPD subtypes showed significant association with BPD II ($OR_{AA+AG \text{ vs. GG}} = 1.21$, 95%CI= 1.06-1.37, $p = 0.003$) but not with BPD I. Although several evidences supported that BDNF factor is involved in BPD pathophysiology like- (i) reduced BDNF levels have been observed in patients with BPD during manic and depressive episodes and these levels have normalized with episode recovery (Cunha et al.,2006; Lin,2009), (ii) post-mortem studies have also demonstrated decreased hippocampal BDNF in patients with BPD (Knable et al.,2004; Dunham et al.,2009), (iii) use of antidepressants and mood stabilizers, e.g. lithium and valproate, to induce expression of neurotrophins (e.g., BDNF) and synaptic changes (Duman et al.,2000) and (iv) modulation of antidepressant-like affects by BDNF genotype and expression was also reported in human studies (Colle et al.,2015; Polyakova et al.,2015). Possible explanation for the lack of association between the Val66Met (rs6265) polymorphism and BPD in present meta-analysis may be due to (i) small sample size in included genetic association studies, (ii) different clinical criteria for selecting BPD patients and (iii) BDNF factor level decreases in subtype BPD II but not in BPD I.

Meta-analysis is an acceptable powerful statistical tool which is used effectively to combine data from several similar case control studies to obtain reliable results. During past two decades, numerous meta-analysis were published which evaluated genetic polymorphism as risk factor for different diseases and disorders- like-schizophrenia (Yadav et al., 2016; Rai et al.,2017), depression (Rai,2014), autism (Rai, 2016; Rai and Kumar,2018), Glucose 6-phosphate deficiency (Kumar et al.,2016), hyperuricemia (Rai, 2016), cleft lip and palate (Rai,2014,2017), male infertility (Rai and Kumar,2017), Down syndrome (Rai,2011; Rai et al., 2017; Rai and Kumar,2018), epilepsy (Rai and Kumar, 2018), Uterine Leiomyoma (Kumar and Rai, 2018), recurrent pregnancy loss (Rai, 2016), breast cancer (Rai,2014; Rai et al.,2017), digestive tract cancer (Yadav et al.,2018), colorectal cancer (Rai, 2015), esophageal cancer (Kumar and Rai,2018), ovary cancer (Rai,2016), and prostate cancer (Yadav et al., 2016) and endometrial cancer (Kumar and Rai,2018) etc.

Despite the clear strengths of present meta-analysis, including relatively large sample sizes and lack of publication bias, the interpretation of results should be done in light of few limitations like-(i) crude ORs without adjustment was used as association measure, adjusted analysis could not be done due to lack of sufficient raw data about related risk factors like substance abuse, alcohol intake etc., (ii) significant heterogeneity was observed in overall meta-analysis,(iii) single gene polymorphism was considered, and (iv) gene-environment interactions were not considered.

Conclusions:

We performed present meta-analysis to find out association between BDNF Val66Met polymorphism and bipolar disorder susceptibility. The results of present meta-analysis reported that BDNF Val66Met polymorphism is not risk factor for bipolar disorder ($OR_{A \text{ vs. G}} = 0.99$, 95%CI= 0.94-1.03, $p = 0.49$). According to DSM IV bipolar disorder is a heterogeneous disease with many subtypes -BPD I, BPD II etc and results or present study also showed that BDNF Val66Met polymorphism may be involved in the pathogenesis of BPD by influencing the susceptibility of specific subtypes such as BP II ($OR = 1.21$, 95% CI=1.06-1.37, $p = 0.003$). Further in subgroup analysis showed no association between Val66Met polymorphism and bipolar disorder risk either from Asian or Caucasian population. In future , studies with larger sample sizes from different ethnic population are required to reach a definitive conclusion regarding this association. Also, it is necessary to take into consideration different inheritance patterns and the interaction of the BDNF gene with the environment.

Declarations:

Abbreviations: BPD- Bipolar disorder; BDNF- Brain derived neurotrophic factor; Val66Met- Valine66Methionine;OR-Odd ratio; CI- Confidence interval

Ethics Approval and consent to participants: In present study , we did not use any human sample, so there is no need of ethics approval and consent of participants.

Consent for Publication: Yes

Competing Interest: No competing interest

Funding: No funding

Authors Contributions: VR and PK designed and wrote this study. VR performed the meta-analysis and FH and PK collected data.

References:

- American Psychiatric Association. Diagnostic and statistical manual of mental disorder-IV-TR. 4th ed. Washington: American Psychiatric Association. 2000.
- Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. *BMC Med Res Methodol*. 2006; 6:50-52.
- Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics*. 1994; 50(4):1088-1101.
- Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. *Nat Genet*. 1999; 22:231-238.
- Carrard A, Salzmann A, Perroud N, Gafner J, Malafosse A, Karege F. Genetic association of the Phosphoinositide-3 kinase in schizophrenia and bipolar disorder and interaction with a BDNF gene polymorphism. *Brain Behav*. 2011; 1:119-124.
- Chang YH, Lee SY, Chen SL, Tzeng NS, Wang TY, Lee IH, et al. Genetic variants of the BDNF and DRD3 genes in bipolar disorder comorbid with anxiety disorder. *J Affect Disord*. 2013; 151:967-972.
- Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. *Science* 2006; 314:140-3.
- Colle R, Deflesselle E, Martin S, David DJ, Hardy P, Taranu A, et al. BDNF/TRKB/P75NTR polymorphisms and their consequences on antidepressant efficacy in depressed patients. *Pharmacogenomics*. 2015;16(9):997-1013.
- Cunha A, Frey B, Andreazza A, Goi J, Rosa A, Goncalves C, et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. *Neurosci Lett*. 2006; 398:215-219.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7: 177-188.
- Duman RS, Malberg J, Nakagawa S, D'Sa C. Neuronal plasticity and survival in mood disorders. *Biol Psychiatry*. 2000, 48:732-739.
- Dunham JS, Deakin JF, Miyajima F, Payton A, Toro CT. Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. *J Psychiatr Res*. 2009; 43(14):1175-84.
- Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. *Cell* 2003;112: 257-269.
- Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997; 315(7109): 629-634.
- Frazier JA, Chiu S, Breeze JL, Makris N, Lange N, Kennedy DN, et al. Structural brain magnetic resonance imaging of limbic and thalamic volumes in pediatric bipolar disorder. *Am J Psychiatry*. 2005; 162: 1256-1265.
- Goldberg TE, Iudicello J, Russo C, Elvevag B, Straub R, Egan MF, et al. BDNF Val66Met polymorphism significantly affects in verbal recognition memory at short and long delays. *Biol Psychol*. 2008;77: 20-4.
- Gonzalez-Castro TB, Nicolini H, Lanzagorta N, Lopez-Narvaez L, Genis A, Pool Garcia S, Tovilla-Zarate CA. The role of brain-derived neurotrophic factor (BDNF) Val66Met genetic polymorphism in bipolar disorder: a case-control study, comorbidities, and meta-analysis of 16,786 subjects. *Bipolar Disord*. 2011; 17: 27-38.
- Goodwin GM. Bipolar disorder. *Dialogues Clin Neurosci*. 2012; 40: 596-598.
- Green EK, Raybould R, Macgregor S, Hyde S, Young AH, O'Donovan MC, et al. Genetic variation of brain-derived neurotrophic factor (BDNF) in bipolar disorder: case-control study of over 3000 individuals from the UK. *Br J Psychiatry*. 2006; 188:21-25.
- Hawton K, Sutton L, Haw C, Sinclair J, Harriss L. Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. *J Clin Psychiatry*. 2005; 66: 693-704.
- Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002; 21: 1539-1558.
- Hong CJ, Huo SJ, Yen FC, Tung CL, Pan GM, Tsai SJ. Association study of a brain-derived neurotrophic-factor genetic polymorphism and mood disorders, age of onset and suicidal behavior. *Neuropsychobiology*. 2003;48:186-189.
- Hosang GM, Uher R, Keers R, Cohen-Woods S, Craig I, Korszun A, et al. Stressful life events and the brain-derived neurotrophic factor gene in bipolar disorder. *J Affect Disord*. 2010; 125: 345-349.
- Huang CC, Chang YH, Lee SY, Chen SL, Chen SH, Chu CH, et al. The interaction between BDNF and DRD2 in bipolar II disorder but not in bipolar I disorder. *Am J Med Genet B Neuropsychiatr Genet*. 2012;159B(5):501-7.
- Kenna HA, Reynolds-May M, Stepanenko A, Ketter TA, Hallmayer J, Rasgon NL. Blood levels of brain derived neurotrophic factor in women with bipolar disorder and healthy control women. *J Affect Disord*. 2014;156:214-8.
- Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. *Arch Gen Psychiatry*. 1994; 51:8-19.
- Kim B, Kim CY, Hong JP, Kim SY, Lee C, Joo YH. Brain-derived neurotrophic factor Val/Met polymorphism and bipolar disorder. Association of the Met allele with suicidal behavior of bipolar patients. *Neuropsychobiology*. 2008;58: 97-103.

Knable MB, Barci BM, Webster MJ, Meador-Woodruff J, Torrey EF. Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. *Mol Psychiatry*. 2004; 9(6): 609-20, 544.

Kumar P, Yadav U, Rai V. Prevalence of glucose-6-phosphate dehydrogenase deficiency in India: An updated meta-analysis. *Egypt J Med Hum Genet*. 2016;17: 295-302.

Kumar P, Rai V. Methylenetetrahydrofolate reductase C677T polymorphism and risk of esophageal cancer: An updated meta-analysis. *Egypt J Med Hum Genet*. 2018; 19(4): 273-284.

Kumar P, Rai V. 2018. Catechol-O-Methyltransferase Val158Met polymorphism and susceptibility to Uterine Leiomyoma. *Jacobs Journal of Gynecology and Obstetrics*. 2018;5(1): 043.

Kunugi H, Iijima Y, Tatsumi M, Yoshida M, Hashimoto R, Kato T, et al. No association between the Val66Met polymorphism of the brain-derived neurotrophic factor gene and bipolar disorder in a Japanese population: a multicenter study. *Biol Psychiatry*. 2004; 56:376–378.

Lee SY, Chen SL, Chen SH et al. Interaction of the DRD3 and BDNF gene variants in subtyped bipolar disorder. *Prog Neuropsychopharmacol Biol Psychiatry*. 2012; 39:382–387.

Lee SY, Chen SL, Wang YS, Chang YH, Huang SY, Tzeng NS, et al. COMT and BDNF interacted in bipolar II disorder not comorbid with anxiety disorder. *Behav Brain Res*. 2013; 237: 243–248.

Lin PT. State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic study. *Neurosci Lett*. 2009; 11;466(3):139-43.

Liu L, Foroud T, Xuei X, Berrettini W, Byerley W, Coryell W, et al. Evidence of association between brain-derived neurotrophic factor gene and bipolar disorder. *Psychiatr Genet*. 2008; 18:267–274.

Lohoff FW, Sander T, Ferraro TN, Dahl JP, Gallinat J, Berrettini WH. Confirmation of association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and bipolar I disorder. *Am J Med Genet Part B: Neuropsychiatr Genet*. 2005;139B:51–3.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *Journal of the National Cancer Institute*. 1959; 22(4):719–748.

Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. *Arch Gen Psychiatry*. 2007; 64:543–552.

Min HJ, Cho HS, Kim SJ, Seok JH, Lee E, Jon DI. Association of the brain-derived neurotrophic factor gene and clinical features of bipolar disorder in Korea. *Clin Psychopharmacol Neurosci*. 2012; 10:163–167.

Morales-Marín ME, Genis-Mendoza AD, Tovilla-Zarate CA, Lanzaagorta N, Escamilla M, Nicolini H. Association between obesity and the brain-derived neurotrophic factor gene polymorphism Val66Met in individuals with bipolar disorder in Mexican population. *Neuropsychiatr Dis Treat*. 2016; 25;12:1843-8.

Nakata K, Ujike H, Sakai A, Uchida N, Nomura A, Imamura T, et al. Association study of the brain-derived neurotrophic factor (BDNF) gene with bipolar disorder. *Neurosci Lett* 2003; 337:17–20.

Nassan M, Croarkin PE, Luby JL, Veldic M, Joshi PT, McElroy SL, et al. Association of brain-derived neurotrophic factor (BDNF) Val66Met polymorphism with early-onset bipolar disorder. *Bipolar Disord*. 2015;17(6):645-52.

Neves FS, Malloy-Diniz L, Romano-Silva MA, Campos SB, Miranda DM, De Marco L, et al. The role of BDNF genetic polymorphisms in bipolar disorder with psychiatric comorbidities. *J Affect Disord*. 2011; 131:307–311.

Neves-Pereira M, Cheung JK, Pasdar A, Zhang F, Breen G, Yates P, et al. BDNF gene is a risk factor for schizophrenia BDNF and Bipolar Disorder 167 in a Scottish population. *Mol Psychiatry*. 2005;10:208-212.

Oswald P, Del-Favero J, Massat I, Souery D, Claes S, Van Broeckhoven C, Endlewiecz J. Non-replication of the brain-derived neurotrophic factor (BDNF) association in bipolar affective disorder: a Belgian patient-control study. *Am J Med Genet B Neuropsychiatr Genet* 2004; 129B:34–35.

Pae CU, Chiesa A, Porcelli S, Han C, Patkar AA, Lee SJ, et al. Influence of BDNF variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. *Neuropsychobiology*. 2012; 65: 1–11.

Pivac N, Kim B, Nedic G, Joo YH, Kozaric-Kovacic D, Hong JP, et al. Ethnic differences in brain-derived neurotrophic factor Val66Met polymorphism in Croatian and Korean healthy participants. *Croat Med J*. 2009;50(1):43-8.

Polyakova M, Stuke K, Schuemberg K, Mueller K, Schoenknecht P, Schroeter ML. BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. *J Affect Disord*. 2015;174:432-40

Post RM. Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. *J Psychiatr Res*. 2007; 41:979–990.

Rai V. Polymorphism in folate metabolic pathway gene as maternal risk factor for Down syndrome. *Int J Biol Med Res*. 2011; 2(4): 1055-1060.

- Rai V. Methylenetetrahydrofolate Reductase A1298C Polymorphism and Breast Cancer Risk: A Meta-analysis of 33 Studies. *Ann Med Health Sci Res.* 2014; 4(6): 841-851.
- Rai V. Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) gene and susceptibility to depression in Asian population: a systematic meta-analysis. *Cell Mol Biol.* 2014; 60 (3): 29-36.
- Rai V. Maternal methylenetetrahydrofolate reductase (MTHFR) gene A1298C polymorphism and risk of nonsyndromic Cleft lip and/or Palate (NSCL/P) in offspring: A meta-analysis. *Asian J Med Sci.* 2014; 6 (1): 16- 21.
- Rai V. Evaluation of the MTHFR C677T Polymorphism as a Risk Factor for Colorectal Cancer in Asian Populations. *Asian Pac J Cancer Prev.* 2015; 16 (18): 8093-8100.
- Rai V (2016) Folate pathway gene methylenetetrahydrofolate reductase C677T polymorphism and Alzheimer disease risk in Asian population. *Ind J Clin Biochem* 31(3):245-52.
- Rai V (2016d) The MTHFR C677T polymorphism and hyperuricemia Risk: a meta-analysis of 558 cases and 912 controls. *Metabolomics* 6: doi.org/10.4172/2153-0769.1000166.
- Rai V. Association of methylenetetrahydrofolate reductase (MTHFR) gene C677T polymorphism with autism: evidence of genetic susceptibility. *Metab Brain Disease* 2016; 31: 727-735.
- Rai V. Methylenetetrahydrofolate reductase C677T polymorphism and recurrent pregnancy loss risk in Asian population: a meta-analysis. *Ind J Clin Biochem.* 2016; 31: 402-13.
- Rai V. Methylenetetrahydrofolate Reductase Gene C677T Polymorphism and Its Association with Ovary Cancer. *J Health Med Informat.* 2016; 7: 3-9.
- Rai V, Yadva U, Kumar P. Null association of maternal MTHFR A1298C polymorphism with Down syndrome pregnancy: An updated meta-analysis. *Egyptian J Med Hum Genet.* 2017; 18(1): 9-18.
- Rai V. Strong association of C677T polymorphism of ethylenetetrahydrofolate reductase gene with nosyndromic cleft lip/palate (nsCL/P). *Ind J Clin Biochem.* 2017; 2: 1-11.
- Rai V, Kumar P. Methylenetetrahydrofolate reductase C677T polymorphism and risk of male infertility in Asian population. *Ind J Clin Biochem.* 2017; 32(3): 253-26.
- Rai V, Yadav U, Kumar P, Yadav SK, Gupat S. Methylenetetrahydrofolate reductase A1298C genetic variant & risk of schizophrenia: A meta-analysis. In *J Med Res.* 2017;145:437- 442.
- Rai V, Yadav U, Kumar P. Impact of catechol-O-methyltransferase Val 158Met (rs4680) polymorphism on breast cancer susceptibility in Asian population. *Asian Pac J Cancer Prev.* 2017; 18(5):1243–50.
- Rai V, Kumar P. Fetal MTHFR C677T polymorphism confers no susceptibility to Down Syndrome: evidence from meta-analysis. *Egyptian J Med Hum Genet.* 2018; 19: 53-58.
- Rai V, Kumar P (2018c) Methylenetetrahydrofolate reductase A1298C polymorphism and autism susceptibility. *Austin Journal of Autism & Related Disabilities* 4: 1048-1053.
- Rai, V., Kumar, P. 2018. Methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to epilepsy. *Neurol Sci.* 2018d; 10.1007/s10072-018-3583-z.
- Schumacher J, Jamra RA, Becker T, Ohlraun S, Klopp N, Binder EB, et al. Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. *Biol Psychiatry.* 2005; 58: 307–314.
- Skibinska M, Hauser J, Czerski PM, Leszczynska-Rodziewicz A, Kosmowska M, Kapelski P, et al. Association analysis of brain-derived neurotrophic factor (BDNF) gene Val66Met polymorphism in schizophrenia and bipolar affective disorder. *World J Biol Psychiatry.* 2004; 5:215–220.
- Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA.* 2000; 283(15) 2008-2012.
- Tang J, Xiao L, Shu C, Wang G, Liu Z, Wang X, Wang H, Bai X. Association of the brain-derived neurotrophic factor gene and bipolar disorder with early age of onset in mainland China. *Neurosci Lett.* 2008; 433:98–102.
- Thakkestian A, McEvoy M, Minelli C, Gibson P, Hancox B, Duffy D. et al. Systematic review and meta-analysis of the association between β 2- adrenoceptor polymorphisms and asthma: a HuGE review. *Am J Epidemiol.* 2005; 162: 201-211.
- Tramontina J, Frey BN, Andreazza AC, Zandona M, Santin A, Kapczinski F. Val66met polymorphism and serum brain-derived neurotrophic factor levels in bipolar disorder. *Mol Psychiatry.* 2007; 12:230–231.

Vincze I, Perroud N, Buresi C, Baud P, Bellivier F, Etain B, Fournier C, et al. Association between brain-derived neurotrophic factor gene and a severe form of bipolar disorder, but no interaction with the serotonin transporter gene. *Bipolar Disord.* 2008; 10: 580–587.

Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Paul Trow P, Schmid CH. Closing the Gap Between Methodologists and End-Users: R as a Computational Back-end. *J Stat Software.* 2013; 49: 1-15.

Wang Z, Li Z, Chen J, Huang J, Yuan C, Hong W, et al. Association of BDNF gene polymorphism with bipolar disorders in Han Chinese population. *Genes Brain Behav.* 2012; 11: 524–528.

Whitehead A. *Meta-Analysis of Controlled Clinical Trials*, John Wiley & Sons Ltd: Chichester, West Sussex, England, 2002.

World Health Organization, 2004. *Changing History*, WHO, Geneva.

Xu J, Liu Y, Wang P, Li S, Wang Y, Li J, Zhou D, et al. Positive association between the brain-derived neurotrophic factor (BDNF) gene and bipolar disorder in the Han Chinese population. *Am J Med Genet B Neuropsychiatr Genet.* 2010; 5: 275–279.

Yadav U, Kumar P, Gupta S, Rai V. Role of MTHFR C677T gene polymorphism in the susceptibility of schizophrenia: An updated meta-analysis. *Asian J Psychiatry.* 2016; 20: 41–51.

Yadav U, Kumar P, Rai V. Role of MTHFR A1298C gene polymorphism in the etiology of prostate cancer: a systematic review and updated meta-analysis. *Egypt J Med Hum Genet.* 2016; 17(2): 141-148.

Yadav U, Kumar P, Rai V. NQO1 gene C609T polymorphism (dbSNP: rs1800566) and digestive tract cancer risk: A Meta analysis. *Nutrition and Cancer.* 2018; 10.1080/01635581.20

Table 1. Details of included studies

Study	Country	Type of Bipolar disorder	Case no.	Control no.	Case Genotypes			Control Genotypes			P- value of HWE
					Val/Val	Val/Me t	Met/Met	Val/Val	Val/Me t	Met/Me t	
Hong et al 2003	China	BPD	192	392	97	212	83	97	212	83	0.1
Nakata et al.,2003	Japan	BPDI	100	190	63	94	33	63	94	33	0.83
Nakata et al.,2003	Japan	BPDII	30	190	63	94	33	63	94	33	0.83
Kunugi et al.,2004	Japan	BPDI	347	588	216	270	102	216	270	102	0.26
Kunugi et al.,2004	Japan	BPDII	172	588	216	270	102	216	270	102	0.26
Oswald et al.,2004	Bulgaria	BPD	108	158	96	57	5	96	57	5	0.31
Skibinska et al.,2004	Wielkopolska	BPD	352	375	248	117	10	248	117	10	0.38
Lohoff et al.,2005,BPI	USA	BPI	621	1001	619	338	44	619	338	44	0.8
Nerves- Pereira et al.,2005	Scotland	BPD	263	350	208	131	11	208	131	11	0.07
Schumacher et al.,2005	Germany	BPD	281	1097	713	351	33	713	351	33	0.19
Green et al.,2006	UK	BPDI	864	2100	1372	660	68	1372	660	68	0.29
Green et al.,2006	UK	BPDII	98	2100	1372	660	68	1372	660	68	0.29
Green et al.,2006	UK	Rapid Cycle BPD	131	2100	1372	660	68	1372	660	68	0.29
Liu et al.,2007	China	BPD	100	100	24	51	25	24	51	25	0.84
Tramontina et al.,2007	Brazil	BPDI	114	137	95	40	2	95	40	2	0.33
Kim et al.,2008	Korea	BPD	169	251	77	114	60	77	114	60	0.16
Vincze et al.,2008	France	BPD	336	313	202	128	6	181	111	21	0.48
Tang et al.,2008	China	BPD	197	208	73	92	32	65	105	38	0.69
Xu et al., 2009	China	BPDI	416	501	135	181	100	141	264	96	0.16
Xu et al.,2009	China	BPII	82	501	19	36	27	141	264	96	0.16
Hosang et al.,2010	UK	BPD	488	598	298	184	6	407	169	22	0.3
Neves et al.,2011	Brazil	BPD	152	160	119	31	2	134	21	5	0.001
Carrad et al.,2011	Switzerland	BPD	109	158	64	42	3	93	56	9	0.88
Huang et al.,2012	Taiwan	BPDI	208	255	44	100	64	61	127	67	0.97
Huang et al.,2012	Taiwan	BPDII	329	255	81	177	71	61	127	67	0.97
Pae et al.,2012	Korea	BPD	132	170	40	70	22	58	81	31	0.77
Wang et al.,2012,BPI	China	BPI	281	386	71	146	64	126	184	76	0.55
Wang et al., 2012,BPII	China	BPII	56	576	11	31	14	184	76	316	0
Lee et al.,2012	China	BPI	268	260	64	130	74	65	127	68	0.71
Lee et al.,2012	China	BPII	436	260	102	230	104	65	127	68	0.71

Min et al.,2012	Korea	BPD	184	214	66	90	28	73	99	42	0.42
Chang et al., 2013,BPI	China	BPI	286	349	81	132	73	99	163	87	0.22
Chang et al.,2013,BPII	China	BPII	681	349	156	356	169	99	163	87	0.22
Lee et al.,2013	China	BPII	431	340	221	178	32	194	116	30	0.04
Castro TB et al.,2014	Mexico	BPI	139	141	97	38	4	94	42	5	0.9
Frazier et al.,2014	USA	BPD	102	135	75	22	5	85	41	9	0.19
Kenna et al.,2014	USA	BPI	12	16	9	3	0	10	5	1	0.73
Kenna et al.,2014	USA	BPII	14	16	7	7	0	10	5	1	0.73
Naasan et al.,2015	USA	BPD	725	764	459	232	34	513	228	23	0.7
Morales-Marín et al.,2016	Mexico	BPD	79	60	63	16	0	34	23	3	0.72

Table 2. Summary estimates for the odds ratio (OR) in various allele/genotype contrasts, the significance level (p value) of heterogeneity test (Q test), and the I² metric: overall analysis

Genetic Models	Fixed effect OR (95% CI), p	Random effect OR (95% CI), p	Heterogeneity p-value (Q test)	I ² (%)	p value of Egger's test)
Allele Contrast (A vs. G)	0.99(0.94-1.03),0.49	0.98(0.93-1.03),0.46	0.02	34.64	0.09
Co-dominant (AG vs. GG)	1.02(0.95-1.07),0.57	1.02(0.93-1.13),0.56	<0.0001	54.68	0.49
Homozygote (AA vs. GG)	0.98(0.89-1.08),0.75	0.98(0.87-1.10),0.74	0.13	20.43	0.05
Dominant (AA+AG vs. GG)	1.00(0.94-1.06),0.89	1.00(0.92-1.09),0.86	0.0007	46.83	0.81
Recessive (AA vs. GG+AG)	0.96(0.89-1.05),47	0.96(0.86-1.06),0.45	0.09	23.92	0.02

Table 3. Summary estimates for the odds ratio (OR) in various allele/genotype contrasts, the significance level (p value) of heterogeneity test (Q test), and the I^2 metric: subgroup analysis based on control source

Genetic Models	Fixed effect OR (95% CI), p	Random effect OR (95% CI), p	Heterogeneity p-value (Q test)	I^2 (%)	p value of Egger's test
Asian studies (studies)					
Allele Contrast (A vs. G)	1.02(0.96-1.07),0.47	1.01(0.96-1.07),0.49	0.42	2.8	0.17
Co-dominant (AG vs. GG)	1.08(0.99-1.18),0.07	1.09(0.95-1.25),0.20	0.001	55.43	0.30
Homozygote (AA vs. GG)	1.05(0.94-1.17),0.34	1.05(0.94-1.17),0.34	0.56	0	0.60
Dominant (AA+AG vs. GG)	1.07(0.98-1.16),0.09	1.07(0.96-1.19),0.20	0.05	35.89	0.45
Recessive (AA vs. GG+AG)	1.01(0.92-1.11),0.79	1.01(0.91-1.11),0.77	0.35	7.62	0.13
Caucasian studies (studies)					
Allele Contrast (A vs. G)	0.93(0.87-0.99),0.03	0.91(0.82-1.01),0.08	0.009	48.77	0.18
Co-dominant (AG vs. GG)	0.96(0.89-1.04),0.34	0.95(0.83-1.08),0.48	0.004	51.91	0.92
Homozygote (AA vs. GG)	0.80(0.65-0.98),0.03	0.77(0.57-1.04),0.09	0.07	33.89	0.12
Dominant (AA+AG vs. GG)	0.94(0.87-1.02),0.14	0.93(0.82-1.05),0.26	0.004	51.96	0.63
Recessive (AA vs. GG+AG)	0.79(0.65-0.95),0.02	0.76(),0.05	0.09	31.66	0.07
BPD I studies (studies)					
Allele Contrast (A vs. G)	0.98(0.93-1.06),0.95	1.00(0.93-1.08),0.90	0.23	21.67	0.80
Co-dominant (AG vs. GG)	0.93(0.85-1.02),0.16	0.94(0.84-1.05),0.33	0.26	18.4	0.36
Homozygote (AA vs. GG)	1.06(0.91-1.23),0.43	1.06(0.91-1.23),0.43	0.77	0	0.76
Dominant (AA+AG vs. GG)	0.95(0.83-1.04),0.26	0.96(0.86-1.07),0.54	0.22	22.19	0.33
Recessive (AA vs. GG+AG)	1.08(0.94-1.20),0.23	1.08(0.94-1.23),0.23	0.84	0	0.44
BPD II studies (studies)					
Allele Contrast (A vs. G)	1.10(1.01-1.13),0.04	1.08(0.93-1.14),0.04	0.29	16.58	0.85
Co-dominant (AG vs. GG)	1.31(1.06-1.60),0.03	1.3(1.1-1.7),0.02	0.14	30.23	0.52
Homozygote (AA vs. GG)	1.11(1.01-1.23),0.03	1.11(0.92-1.33),0.04	0.45	0	0.93
Dominant (AA+AG vs. GG)	1.21(1.06-1.37),0.003	1.21(1.01-1.46),0.03	0.07	42.67	0.27
Recessive (AA vs. GG+AG)	0.96(0.83-1.12),0.06	0.97(0.80-1.19),0.08	0.17	28.93	0.73
BPD studies (studies)					

Allele Contrast (A vs. G)	0.95(0.89-1.02),0.24	0.93(0.85-1.02),0.15	0.06	37.12	0.0008
Co-dominant (AG vs. GG)	1.02(0.93-1.12),0.63	0.98(0.86-1.13),0.87	0.03	42.87	0.22
Homozygote (AA vs. GG)	0.82(0.68-0.98),0.03	0.76(0.62-1.01)0.07	0.07	35.97	0.06
Dominant (AA+AG vs. GG)	0.99(0.90-1.08),0.88	0.95(0.84-1.08),0.48	0.03	41.18	0.08
Recessive (AA vs. GG+AG)	0.82(0.70-0.96),0.02	0.80(0.64-0.99),0.05	0.07	35.96	0.02

Figure 1. Flow Diagram of Study Search and Selection Process.

Figure 2. Random effect Forest plot of allele contrast model (A vs. G) of total 40 studies of BDNF Val66Met(G196A) polymorphism.

Figure 3. Random effect Forest plot of dominant model (AA+AG vs. GG) of 21 studies of Asian population of BDNF Val66Met(G196A) polymorphism.

Figure 4. Random effect Forest plot of dominant model (AA+AG vs. GG) of 19 studies of Caucasian population of BDNF Val66Met(G196A) polymorphism.